Wolfgang Blau

1.2k total citations
19 papers, 382 citations indexed

About

Wolfgang Blau is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Wolfgang Blau has authored 19 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 6 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in Wolfgang Blau's work include Lymphoma Diagnosis and Treatment (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Wolfgang Blau is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Wolfgang Blau collaborates with scholars based in Germany, Switzerland and United States. Wolfgang Blau's co-authors include Kathrin Rieger, Wolfgang Knauf, Sixten Körper, Mathias Rummel, Thomas Fietz, B. Reufi, Eckhard Thiel, Ulrich Kaiser, Martina Stauch and Ulrich von Gruenhagen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Wolfgang Blau

19 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wolfgang Blau Germany	9	188	166	156	80	75	19	382
Parth Desai United States	12	189 1.0×	289 1.7×	295 1.9×	91 1.1×	73 1.0×	52	576
Sharathkumar Bhagavathi United States	14	268 1.4×	140 0.8×	375 2.4×	79 1.0×	54 0.7×	32	544
Tariq Muzzafar United States	14	176 0.9×	152 0.9×	220 1.4×	95 1.2×	149 2.0×	34	507
Emmanuelle Nicolas‐Virelizier France	13	195 1.0×	285 1.7×	424 2.7×	54 0.7×	56 0.7×	58	585
Noraidah Masir Malaysia	12	101 0.5×	163 1.0×	205 1.3×	90 1.1×	23 0.3×	48	396
Atsushi Shinagawa Japan	13	112 0.6×	144 0.9×	134 0.9×	142 1.8×	208 2.8×	39	446
Eisuke Shiozawa Japan	12	69 0.4×	182 1.1×	189 1.2×	75 0.9×	44 0.6×	39	366
Dima El‐Sharkawi United Kingdom	13	158 0.8×	140 0.8×	216 1.4×	104 1.3×	122 1.6×	64	467
S. Molica Italy	11	187 1.0×	196 1.2×	286 1.8×	125 1.6×	143 1.9×	26	545
Lauris Gastaud France	12	70 0.4×	191 1.2×	110 0.7×	64 0.8×	79 1.1×	36	395

Countries citing papers authored by Wolfgang Blau

Since Specialization

Citations

This map shows the geographic impact of Wolfgang Blau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Blau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Blau more than expected).

Fields of papers citing papers by Wolfgang Blau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Blau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Blau. The network helps show where Wolfgang Blau may publish in the future.

Co-authorship network of co-authors of Wolfgang Blau

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Blau. A scholar is included among the top collaborators of Wolfgang Blau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Blau. Wolfgang Blau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Al‐Batran, Salah‐Eddin, Sylvie Lorenzen, Jorge Riera, et al.. (2024). Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.. Journal of Clinical Oncology. 42(17_suppl). LBA4001–LBA4001. 13 indexed citations

Gaska, Tobias, Maximilian Reichert, Michael Quante, et al.. (2023). FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).. Journal of Clinical Oncology. 41(16_suppl). 4021–4021. 5 indexed citations

Pscherer, Sibylle, Ulrike Gamerdinger, Andrea Teigler‐Schlegel, et al.. (2021). Parallel evaluation of cell‑based phage display panning strategies: Optimized selection and depletion steps result in AML blast‑binding consensus antibodies. Molecular Medicine Reports. 24(5). 5 indexed citations

Grohé, Christian, Wolfgang Blau, Wolfgang Gleiber, et al.. (2020). Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).. Journal of Clinical Oncology. 38(15_suppl). 9604–9604. 5 indexed citations

Al‐Batran, Salah‐Eddin, Ralf‐Dieter Hofheinz, Alexander Reichart, et al.. (2020). Real-life results from the prospective QoliXane trial of the platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry.. Journal of Clinical Oncology. 38(15_suppl). 4625–4625. 1 indexed citations

Grohé, Christian, Wolfgang Blau, Wolfgang Gleiber, et al.. (2019). Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.. Journal of Clinical Oncology. 37(15_suppl). 9074–9074. 3 indexed citations

Bräuninger, Andreas, Wolfgang Blau, Alexander Brobeil, et al.. (2018). Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines. Journal of Molecular Diagnostics. 20(3). 344–354. 6 indexed citations

Tur, Mehmet Kemal, Alexander Brobeil, Benjamin Etschmann, et al.. (2018). Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Head & Neck. 40(6). 1109–1119. 10 indexed citations

Mueller, Daniel, Stefan Paul Moenig, Arndt Vogel, et al.. (2017). The “RENAISSANCE” Trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction—A phase III trial of the German AIO/CAO-V/CAOGI.. Journal of Clinical Oncology. 35(15_suppl). TPS4140–TPS4140. 2 indexed citations

10.

Rummel, Mathias, Georg Maschmeyer, Arnold Ganser, et al.. (2017). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.. Journal of Clinical Oncology. 35(15_suppl). 7501–7501. 47 indexed citations

11.

Rummel, Mathias, Ulrich Kaiser, Christina Balser, et al.. (2015). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology. 17(1). 57–66. 110 indexed citations

12.

Blau, Wolfgang, et al.. (2015). Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. mAbs. 7(2). 390–402. 18 indexed citations

13.

Gamerdinger, Ulrike, Alexander Brobeil, Mehmet Kemal Tur, et al.. (2014). Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. Pathology - Research and Practice. 210(6). 369–376. 10 indexed citations

14.

Dornes, Christian, et al.. (2014). Factor XIII Deficiency in Patients with Acute Leukemia: One out of Three Is Presenting with Deficiency. Blood. 124(21). 1528–1528. 2 indexed citations

15.

Rummel, Mathias, Christina Balser, Ulrich Kaiser, et al.. (2014). Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 124(21). 145–145. 4 indexed citations

16.

Rummel, Mathias, Georg Maschmeyer, Arnold Ganser, et al.. (2014). Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. Blood. 124(21). 4407–4407. 10 indexed citations

17.

Brobeil, Alexander, Wolfgang Blau, Mathias Rummel, et al.. (2011). PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia. Leukemia Research. 35(10). 1367–1375. 14 indexed citations

18.

Rieger, Kathrin, Thomas Fietz, Sixten Körper, et al.. (2005). Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Experimental Hematology. 33(5). 605–611. 115 indexed citations

19.

Knauf, Wolfgang, Kathrin Rieger, Wolfgang Blau, et al.. (2004). Remission Induction Using Alemtuzumab can Permit Chemotherapy-refractory Chronic Lymphocytic Leukemia (CLL) Patients to Undergo Allogeneic Stem Cell Transplantation. Leukemia & lymphoma. 45(12). 2455–2458. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact